Evidence map›Paper›PMID 27391431›Full record

SynthesisOncotarget2016

HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review.

Tengyun Wu, Wei Zhang, Geliang Yang, Huijun Li, Qi Chen, Ruixiang Song, Lin Zhao

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Progress in the mechanistic understanding of NETs formation in cancer.Medical oncology (Northwood, London, England) · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Methylation ofJournal of translational internal medicine · 2024
    Article
  19. Review
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tengyun WuAir Force General Hospital of Chinese People's Liberation Army, Beijing 100142, China.
Wei ZhangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Geliang YangDepartment of Integrated Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Huijun LiThe Wright Center, Scranton, Pennsylvania 18510, USA.
Qi ChenDepartment of Health Statistics, Faculty of Health Service, Second Military Medical University, Shanghai 200433, China.
Ruixiang SongDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Lin ZhaoDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As there are millions of cancer deaths every year, it is of great value to identify applicable prognostic biomarkers. As an important alarm, the prognostic role of high mobility group box 1 (HMGB1) in cancer remains controversial. We aim to assess the association of HMGB1 expression with prognosis in cancer patients. Systematic literature searches of PubMed, Embase and Web of Science databases were performed for eligible studies of HMGB1 as prognostic factor in cancer. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the influence of HMGB1 expression on overall survival (OS) and progression-free survival (PFS) in cancer patients. 18 studies involving 11 different tumor types were included in meta-analysis. HMGB1 overexpression was significantly associated with poorer OS (HR: 1.99; 95% CI, 1.71-2.31) and PFS (HR: 2.26; 95% CI, 1.65-3.10) irrespective of cancer types including gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, nasopharyngeal carcinoma, head and neck squamous-cell carcinoma, esophageal cancer, malignant pleural mesothelioma, bladder cancer, prostate cancer, and cervical carcinoma. Subgroup analyses indicated geographical area and size of studies did not affect the prognostic effects of HMGB1 for OS. Morever, HMGB1 overexpression had a consistent correlation with poorer OS when detected by immunohistochemistry in tissues and enzyme-linked immunosorbent assay in serum, whereas the correlation did not exist by quantitative real-time reverse-transcription polymerase chain reaction in tissues. HMGB1 overexpression is associated with poorer prognosis in patients with various types of cancer, suggesting that it is a prognostic factor and potential biomarker for survival in cancer.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorDisease-Free SurvivalGeographyHMGB1 ProteinHumansNeoplasmsPrognosisProportional Hazards ModelsTreatment OutcomeBiomarkers, TumorHMGB1 ProteinHMGB1 protein, humancancerhigh mobility group box 1meta-analysisprognosis factorsurvival

Identifiers

PMID27391431
PMCPMC5226592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.